Market Intelligence, Clinical Progress, and High-Purity Reagents for Thiopurine Sensitivity and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NUDT15 drug discovery and pharmacogenomics validation. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NUDT15 Wild-Type (WT) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic assays. |
View NUDT15 Products |
| Mutant Antigen | NUDT15 Mutant (R139C / R139H) Recombinant Protein Sequence verified. Crucial for pharmacogenomic screening and stability profiling. |
View NUDT15 Products |
| Gene Delivery | NUDT15 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View NUDT15 Products |
| Validator | NUDT15 siRNA Set For target knockdown verification in thiopurine sensitivity assays. |
View NUDT15 Products |
| Related Target A | TPMT (Thiopurine S-methyltransferase) Primary co-modifier of thiopurine toxicity; essential for parallel pharmacogenomic profiling. |
View TPMT Products |
| Related Target B | NUDT1 (MTH1) Sister pyrophosphatase in nucleotide pool sanitation; critical for selectivity counter-screening. |
View NUDT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against NUDT family homologs | High-purity recombinant NUDT15 WT and NUDT1 (MTH1) proteins strictly verified by Mass Spectrometry. |
| Pharmacogenomics (PGx) variant screening | Recombinant NUDT15 clinical mutants (R139C, R139H) available with guaranteed sequence accuracy and >95% purity. |
| In vitro enzymatic assay reproducibility | Batch-to-batch consistency with strict endotoxin control (<1 EU/µg) and native-like folding. |
| Lack of reliable negative controls | Sequence-verified siRNA sets included to confirm knockdown specificity in cell-based assays. |
Live NUDT15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical significance of NUDT15 has transitioned from a pure pharmacogenomics (PGx) biomarker to an active therapeutic target in oncology. NUDT15 hydrolyzes active thiopurine metabolites (such as TGTP and dTGTP), preventing their incorporation into DNA and avoiding subsequent mismatch repair-mediated cell death. Consequently, patients harboring loss-of-function NUDT15 variants (e.g., NUDT15*3 / R139C) experience severe, life-threatening myelosuppression when treated with standard doses of thiopurines (6-mercaptopurine, azathioprine).
The next wave of R&D leverages this biology by developing potent, selective small-molecule NUDT15 inhibitors. By combining these inhibitors with low-dose thiopurines, researchers aim to sensitize cancer cells (specifically in acute lymphoblastic leukemia and inflammatory bowel disease-associated malignancies) while mitigating systemic toxicity. Additionally, structural biology efforts are focused on characterizing how clinical variants alter protein stability, requiring robust mutant protein panels for drug screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Karolinska Institutet, Biotech Startups | Acute Lymphoblastic Leukemia (ALL), Solid Tumors | Enzymatic activity assays requiring high-purity WT and mutant (R139C) proteins. |
| Companion Diagnostics (PGx) | Diagnostic Developers | Thiopurine Dosing Stratification | Recombinant mutant proteins (R139C, R139H) for antibody generation and assay calibration. |
| Combination Therapies | Academic Medical Centers | Hematological Malignancies | Lentivirus for stable cell line construction to model NUDT15 deficiency and rescue phenotypes. |